Equillium, Inc. (LON:0A4D)

Market Cap	99.22M +357.5%
Revenue (ttm)	3.27M -90.4%
Net Income	-18.16M
EPS	-0.43
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,299
Average Volume	4,490
Open	2.080
Previous Close	2.129
Day's Range	2.080 - 2.230
52-Week Range	0.280 - 2.610
Beta	1.83
RSI	63.17
Earnings Date	Mar 23, 2026

About Equillium

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 35
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4D

Financial Performance

In 2024, Equillium's revenue was $41.10 million, an increase of 13.89% compared to the previous year's $36.08 million. Losses were -$8.07 million, -39.51% less than in 2023.

Financial numbers in USD